Search Result

Results for "

VHL-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (2) Casein Kinase (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) Epigenetic Reader Domain (1) FAK (1) HIF/HIF Prolyl-Hydroxylase (2) Ligands for E3 Ligase (11) MDM-2/p53 (3) NF-κB (1) p38 MAPK (1) Phosphatase (2) PROTACs (9) Reference Standards (1) Ser/Thr Kinase (1) SHP2 (1) SWI/SNF Complex (1) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (1) Inflammation/Immunology (1)

By Targets:

Akt (1)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (2)

Casein Kinase (1)

E1/E2/E3 Enzyme (1)

E3 Ligase Ligand-Linker Conjugates (1)

Epigenetic Reader Domain (1)

FAK (1)

HIF/HIF Prolyl-Hydroxylase (2)

Ligands for E3 Ligase (11)

MDM-2/p53 (3)

NF-κB (1)

p38 MAPK (1)

Phosphatase (2)

PROTACs (9)

Reference Standards (1)

Ser/Thr Kinase (1)

SHP2 (1)

SWI/SNF Complex (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (21)

Cardiovascular Disease (1)

Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-120217

VH032 Maximum Cited Publications 9 Publications Verification	Ligands for E3 Ligase	Cancer
VH032 is a VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. VH032 is a VHL/HIF-1α interaction inhibitor with a K_d[1] .

HY-112078

(S,R,S)-AHPC-Me VHL ligand 2; E3 ligase Ligand 1A	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM .

HY-156106

*VHL-IN-1*	HIF/HIF Prolyl-Hydroxylase Ligands for E3 Ligase E1/E2/E3 Enzyme	Cancer
VHL-IN-1 (Compound 30) is an E3 ligase VHL inhibitor with a K_d value of 37 nM. VHL-IN-1 blocks VHL-mediated ubiquitination and degradation of *HIF-1α. VHL-IN-1* stabilizes the protein levels of *HIF-1α* and hydroxylated *HIF-1α, and induces the transcriptional activity of HIF-1α. VHL-IN-1* can be used for PROTAC development. VHL-IN-1 is applicable for cancer research ^[1].

HY-42424

(S,R,S)-AHPC-Me hydrochloride VHL ligand 2 hydrochloride; E3 ligase Ligand 1	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM .

HY-101763A

(S,R,S)-AHPC monohydrochloride 2 Publications Verification VH032-NH2 monohydrochloride; VHL ligand 1 monohydrochloride	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC (VH032-NH2; VHL ligand 1) hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein .

HY-125845A

(S,S,S)-AHPC hydrochloride 2 Publications Verification (S,S,S)-VH032-NH2 hydrochloride	Ligands for E3 Ligase	Cancer
(S,S,S)-AHPC ((S,S,S)-VH032-NH2) hydrochloride is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC (Compound 27) is a ligand used as a negative control for (S,R,S)-AHPC (HY-125845). (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein .

HY-171658

R1-ICR-5	PROTACs Ser/Thr Kinase TNF Receptor Toll-like Receptor (TLR) NF-κB p38 MAPK	Inflammation/Immunology Cancer
R1-ICR-5 is a highly selective *RIPK1* PROTAC degrader. Mediated by VHL, R1-ICR-5 induces the degradation of RIPK1, which in turn dysregulates the *TNFR1* and TLR3/4 signaling hubs, enhances the signaling outputs of NF-κB, MAPK and IFN, and simultaneously promotes RIPK3 activation and necroptosis (necroptosis). R1-ICR-5 can be used in the research of triple-negative breast cancer and skin inflammation ^[1].

HY-119932

PROTAC FAK degrader 1 5+ Cited Publications	PROTACs FAK Akt	Cancer
PROTAC FAK degrader 1 (Compound PROTAC-3) is a selective and effective degrader of Fak PROTAC with a DC₅₀ of 3.0 nM. PROTAC FAK degrader 1 reduces the ability of cancer cells to migrate and invade. PROTAC FAK degrader 1 can be used in the study of tumor. (Pink: Fak ligand (HY-44146); Black: Linker (HY-44141); Blue: VHL ligand 1 (HY-125845)) ^[1].

HY-145162

SHP2-D26 1 Publications Verification	PROTACs SHP2 Phosphatase	Cancer
SHP2-D26 is a first, potent and effective SHP2 PROTAC degrader. SHP2-D26 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins. SHP2-D26 is also neddylation- and proteasome-dependent. SHP2-D26 can be used for the study of esophageal cancer and acute myeloid leukemia (Pink: SHP2 ligand (HY-176797); Blue: VHL ligand (HY-150803); Black: linker) ^[1].

HY-158684

YX-02-030	PROTACs MDM-2/p53 Apoptosis	Cancer
YX-02-030 is a VHL-dependent MDM2 PROTAC degrader with a K_d of 35 nM. YX-02-030 recruits the VHL E3 ligase to form a ternary complex, leading to ubiquitination and proteasome-mediated degradation of MDM2. YX-02-030 inhibits MDM2-p53 and VHL-HIF1α binding with IC₅₀ values of 63 and 1350 nM. YX-02-030 activates TAp73, upregulates p53 family target genes and induces apoptosis. YX-02-030 demonstrates on-target efficacy in TNBC xenograft-bearing mice, extending survival without normal cell toxicity ^[1].

HY-170824

SMD-3236	PROTACs SWI/SNF Complex Epigenetic Reader Domain	Cancer
SMD-3236 is a SMARCA2 PROTAC degrader with a DC₅₀ of 0.5 nM, a D_max of 98%, and an IC₅₀ of 42.2 nM against human SMARCA2. SMD-3236 induces proteasome- and ubiquitin-like modification-dependent degradation of SMARCA2 protein by binding to SMARCA2 and *VHL-1. SMD-3236 inhibits the growth of SMARCA4-deficient cancer cells. SMD-3236 induces significant and persistent depletion of SMARCA2* in tumor tissues. SMD-3236 suppresses tumor growth in SMARCA4-deficient human cancer xenograft models. SMD-3236 can be used in research related to SMARCA4-deficient cancers such as melanoma, non-small cell lung cancer, and acute myeloid leukemia ^[1].

HY-136055

(S,R,S)-AHPC-C5-COOH VH032-C5-COOH	E3 Ligase Ligand-Linker Conjugates HIF/HIF Prolyl-Hydroxylase	Cancer
(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of *VHL/HIF-1α* interaction with a K_d of 185 nM, has the potential for the study of anemia and ischemic diseases ^[1].

HY-42424A

(S,R,S)-AHPC-Me dihydrochloride VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM .

HY-157512

SJF-0661	Ligands for E3 Ligase	Cancer
SJF-0661 is a variant of the von Hippel-Lindau (VHL) protein ligand with no targeted degradation ability and can be used as a control reagent for the VHL ubiquitin ligase ligand. SJF-0661 is a variant obtained by inverting the stereocenter of the key hydroxyproline group in the VHL ligand .

HY-164977

JCS-1	PROTACs Phosphatase	Cancer
JCS-1 is a potent DcpS PROTAC degrader. JCS-1 non-covalently binds DcpS with a RG3039-based warhead and recruits the E3 ligase VHL. JCS-1 promotes ubiquitination and degradation of DcpS at nanomolar concentrations (DC₅₀ in MOLM-14 cells: 87 nM). JCS-1 can be used for the research of AML and other DcpS-dependent genetic disorders (Pink: DcpS ligand (HY-102020); Blue: E3 ligase VHL ligand (HY-151227); Black: linker (HY-141230)) ^[1].

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent MDM2 inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels ^[1].

HY-138678

(R,S,S)-VH032	Ligands for E3 Ligase	Cancer
(R,S,S)-VH032 is Ligand for E3 Ligase used in the synthesis of PROTACs. VH032 is a VHL ligand and VHL/HIF-1α interaction inhibitor that recruits von Hippel-Lindau (VHL) proteins. (R,S,S)-VH032 synthesizes the tau-targeting small molecule PROTAC C004019 (HY-138669) ^[1].

HY-170859A

AH081	PROTACs Casein Kinase	Cancer
AH081 (Compound 38) is a *CK1δ/ε* PROTAC degrader. AH081 is the negative control compound of AH078 (HY-170859). AH081 has inhibitory but no degradation activity for CK1δ/ε by using an inactive stereoisomer of the VHL ligand . Pink: CK1δ/ε ligand (HY-148251); Blue: VHL ligase ligand (HY-125845B); Black: linker

HY-162450

Antitumor agent-150	PROTACs MDM-2/p53 Apoptosis	Cancer
Antitumor agent-150 (V10), an anti-breast cancer agent, is a PROTAC-based MDM2 protein degrader (Red: Ganoderic acid A; Black: 4O-PEG linker; Blue: VHL ligand) .

HY-146022

SIAIS117	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
SIAIS117 is a potent Brigatinib-PROTAC degrader. SIAIS117 is a ALK PROTAC based on Brigatinib and VHL-1 conjunction. SIAIS117 can degrade ALK G1202R point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines. SIAIS117 has the potentially anti-proliferation ability of small cell lung cancer ^[1].

HY-125845B

(S,S,S)-AHPC (S,S,S)-VH032-NH2	Ligands for E3 Ligase	Others
(S,S,S)-AHPC ((S,S,S)-VH032-NH2) is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC (Compound 27) is a ligand used as a negative control for (S,R,S)-AHPC (HY-125845). (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein .

HY-101763AR

(S,R,S)-AHPC monohydrochloride (Standard) VH032-NH2 monohydrochloride (Standard); VHL ligand 1 monohydrochloride (Standard)	Reference Standards Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC monohydrochloride (Standard) (VH032-NH2 monohydrochloride (Standard)) is the analytical standard of (S,R,S)-AHPC monohydrochloride (HY-101763A). This product is intended for research and analytical applications. (S,R,S)-AHPC (VH032-NH2; VHL ligand 1) hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein .

Cat. No.	상품명	Target	Research Area

HY-P5908

DEALA-Hyp-YIPD	Peptides	Cardiovascular Disease
DEALA-Hyp-YIPD is an HIF-1α peptide that inhibits VHL/HIF-1α interaction with an IC₅₀ of 0.91 μM and a K_d of 180 nM ^[1].

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Name
이메일 *

	Sorry, but the email address you supplied was invalid.